Rabeprazole in a one-week eradication therapy of Helicobacter pylori: Comparison of different dosages

Francesco Di Mario, Nadia Dal Bò, Giovanni Aragona, Ali M. Moussa, Veronica Iori, Giulia M. Cavestro, Alberto Pilotto, Gioacchino Leandro, Marilisa Franceschi, Massimo Rugge, Angelo Franzè

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Aim: Many data regarding omeprazole-, lanzoprazole- and pantoprazole-based triple therapy for Helicobacter pylori (H. pylori) eradication have been reported, but there is few data present regarding rabeprazole (R). We report the efficacy and tolerability of rabeprazole in different dosages in association with clarithromycin (C) and tinidazole (T) in H. pylori eradication. Design and Methods: Ninety-four H. pylori-positive patients with dyspeptic symptoms were enrolled and randomly allocated to eradication therapy in two different one-week regimens. In regimen A, 47 patients received R 20 mg b.i.d, C 500 mg b.i.d and T 500 mg b.i.d, while in regimen B, 47 patients received R 10 mg b.i.d, C 500 mg b.i.d and T 500 mg b.i.d. Eradication of H. pylori was evaluated by a 13C urea breath test (UBT) two months after the end of the therapy. Results: Four patients (two in each regimen) did not complete treatment. The H. pylori eradication rate was 91.4% in group A compared to 89.3% in group B (P-value not significant). Minor side-effects were reported in 4.2% of group A and 6.4% of group B patients. Conclusion: Rabeprazole showed good efficacy and tolerability in one-week H. pylori therapy at 20 mg b.i.d and 10 mg b.i.d, suggesting the use of the lower dosage.

Original languageEnglish
Pages (from-to)783-786
Number of pages4
JournalJournal of Gastroenterology and Hepatology
Volume18
Issue number7
DOIs
Publication statusPublished - Jul 1 2003

Fingerprint

Rabeprazole
Helicobacter pylori
Therapeutics
Tinidazole
Breath Tests
Clarithromycin
Omeprazole
Urea

Keywords

  • Different dosage
  • Eradication therapy
  • Helicobacter pylori
  • Rabeprazole

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Rabeprazole in a one-week eradication therapy of Helicobacter pylori : Comparison of different dosages. / Di Mario, Francesco; Dal Bò, Nadia; Aragona, Giovanni; Moussa, Ali M.; Iori, Veronica; Cavestro, Giulia M.; Pilotto, Alberto; Leandro, Gioacchino; Franceschi, Marilisa; Rugge, Massimo; Franzè, Angelo.

In: Journal of Gastroenterology and Hepatology, Vol. 18, No. 7, 01.07.2003, p. 783-786.

Research output: Contribution to journalArticle

Di Mario, F, Dal Bò, N, Aragona, G, Moussa, AM, Iori, V, Cavestro, GM, Pilotto, A, Leandro, G, Franceschi, M, Rugge, M & Franzè, A 2003, 'Rabeprazole in a one-week eradication therapy of Helicobacter pylori: Comparison of different dosages', Journal of Gastroenterology and Hepatology, vol. 18, no. 7, pp. 783-786. https://doi.org/10.1046/j.1440-1746.2003.03035.x
Di Mario, Francesco ; Dal Bò, Nadia ; Aragona, Giovanni ; Moussa, Ali M. ; Iori, Veronica ; Cavestro, Giulia M. ; Pilotto, Alberto ; Leandro, Gioacchino ; Franceschi, Marilisa ; Rugge, Massimo ; Franzè, Angelo. / Rabeprazole in a one-week eradication therapy of Helicobacter pylori : Comparison of different dosages. In: Journal of Gastroenterology and Hepatology. 2003 ; Vol. 18, No. 7. pp. 783-786.
@article{963708fc641c4ef98b50a88e895f58a1,
title = "Rabeprazole in a one-week eradication therapy of Helicobacter pylori: Comparison of different dosages",
abstract = "Aim: Many data regarding omeprazole-, lanzoprazole- and pantoprazole-based triple therapy for Helicobacter pylori (H. pylori) eradication have been reported, but there is few data present regarding rabeprazole (R). We report the efficacy and tolerability of rabeprazole in different dosages in association with clarithromycin (C) and tinidazole (T) in H. pylori eradication. Design and Methods: Ninety-four H. pylori-positive patients with dyspeptic symptoms were enrolled and randomly allocated to eradication therapy in two different one-week regimens. In regimen A, 47 patients received R 20 mg b.i.d, C 500 mg b.i.d and T 500 mg b.i.d, while in regimen B, 47 patients received R 10 mg b.i.d, C 500 mg b.i.d and T 500 mg b.i.d. Eradication of H. pylori was evaluated by a 13C urea breath test (UBT) two months after the end of the therapy. Results: Four patients (two in each regimen) did not complete treatment. The H. pylori eradication rate was 91.4{\%} in group A compared to 89.3{\%} in group B (P-value not significant). Minor side-effects were reported in 4.2{\%} of group A and 6.4{\%} of group B patients. Conclusion: Rabeprazole showed good efficacy and tolerability in one-week H. pylori therapy at 20 mg b.i.d and 10 mg b.i.d, suggesting the use of the lower dosage.",
keywords = "Different dosage, Eradication therapy, Helicobacter pylori, Rabeprazole",
author = "{Di Mario}, Francesco and {Dal B{\`o}}, Nadia and Giovanni Aragona and Moussa, {Ali M.} and Veronica Iori and Cavestro, {Giulia M.} and Alberto Pilotto and Gioacchino Leandro and Marilisa Franceschi and Massimo Rugge and Angelo Franz{\`e}",
year = "2003",
month = "7",
day = "1",
doi = "10.1046/j.1440-1746.2003.03035.x",
language = "English",
volume = "18",
pages = "783--786",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Rabeprazole in a one-week eradication therapy of Helicobacter pylori

T2 - Comparison of different dosages

AU - Di Mario, Francesco

AU - Dal Bò, Nadia

AU - Aragona, Giovanni

AU - Moussa, Ali M.

AU - Iori, Veronica

AU - Cavestro, Giulia M.

AU - Pilotto, Alberto

AU - Leandro, Gioacchino

AU - Franceschi, Marilisa

AU - Rugge, Massimo

AU - Franzè, Angelo

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Aim: Many data regarding omeprazole-, lanzoprazole- and pantoprazole-based triple therapy for Helicobacter pylori (H. pylori) eradication have been reported, but there is few data present regarding rabeprazole (R). We report the efficacy and tolerability of rabeprazole in different dosages in association with clarithromycin (C) and tinidazole (T) in H. pylori eradication. Design and Methods: Ninety-four H. pylori-positive patients with dyspeptic symptoms were enrolled and randomly allocated to eradication therapy in two different one-week regimens. In regimen A, 47 patients received R 20 mg b.i.d, C 500 mg b.i.d and T 500 mg b.i.d, while in regimen B, 47 patients received R 10 mg b.i.d, C 500 mg b.i.d and T 500 mg b.i.d. Eradication of H. pylori was evaluated by a 13C urea breath test (UBT) two months after the end of the therapy. Results: Four patients (two in each regimen) did not complete treatment. The H. pylori eradication rate was 91.4% in group A compared to 89.3% in group B (P-value not significant). Minor side-effects were reported in 4.2% of group A and 6.4% of group B patients. Conclusion: Rabeprazole showed good efficacy and tolerability in one-week H. pylori therapy at 20 mg b.i.d and 10 mg b.i.d, suggesting the use of the lower dosage.

AB - Aim: Many data regarding omeprazole-, lanzoprazole- and pantoprazole-based triple therapy for Helicobacter pylori (H. pylori) eradication have been reported, but there is few data present regarding rabeprazole (R). We report the efficacy and tolerability of rabeprazole in different dosages in association with clarithromycin (C) and tinidazole (T) in H. pylori eradication. Design and Methods: Ninety-four H. pylori-positive patients with dyspeptic symptoms were enrolled and randomly allocated to eradication therapy in two different one-week regimens. In regimen A, 47 patients received R 20 mg b.i.d, C 500 mg b.i.d and T 500 mg b.i.d, while in regimen B, 47 patients received R 10 mg b.i.d, C 500 mg b.i.d and T 500 mg b.i.d. Eradication of H. pylori was evaluated by a 13C urea breath test (UBT) two months after the end of the therapy. Results: Four patients (two in each regimen) did not complete treatment. The H. pylori eradication rate was 91.4% in group A compared to 89.3% in group B (P-value not significant). Minor side-effects were reported in 4.2% of group A and 6.4% of group B patients. Conclusion: Rabeprazole showed good efficacy and tolerability in one-week H. pylori therapy at 20 mg b.i.d and 10 mg b.i.d, suggesting the use of the lower dosage.

KW - Different dosage

KW - Eradication therapy

KW - Helicobacter pylori

KW - Rabeprazole

UR - http://www.scopus.com/inward/record.url?scp=0042202170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042202170&partnerID=8YFLogxK

U2 - 10.1046/j.1440-1746.2003.03035.x

DO - 10.1046/j.1440-1746.2003.03035.x

M3 - Article

C2 - 12795749

AN - SCOPUS:0042202170

VL - 18

SP - 783

EP - 786

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 7

ER -